May 27, 2025 – Sanofi and Vietnam Vaccine JSV (VNVC) have launched a new state-of-the-art vaccine manufacturing plant in Vietnam. The facility, located in Long An province, was inaugurated on Tuesday during a visit by French President Emmanuel Macron.
The new facility is designed to produce and supply vaccines for domestic use and export. It is estimated to produce around 100 million doses annually, with operations set to begin by the end of 2027.
Located to support Vietnam’s expanding healthcare demand, the facility boosts local vaccine self-reliance as well as strengthens the global vaccine supply channels. This initiative reflects Sanofi’s ongoing efforts to expand its presence in emerging markets and solidify its position as a global vaccine leader.
The launch takes place at a time when global attention on vaccine access and preparedness is at an all-time high, especially in the wake of recent pandemics. The new facility will utilize advanced technology combined with Sanofi’s deep expertise in vaccines. Its goal is to enhance Vietnam’s role as a key regional center for pharmaceutical innovation and manufacturing.
The initiative supports VNVC’s mission to enhance immunization access throughout Vietnam. It aligns with government objectives to attract high-quality foreign investment in biotechnology and life sciences sectors.
VNVC and Sanofi also signed an agreement on transferring Sanofi's vaccine production technology to the Vietnam factory. The new technology will be employed to produce some important Sanofi vaccines like 6-in-1 vaccine for children, meningococcal meningitis vaccine, and flu vaccine for children and adults.
Speaking on the occasion, Mr. Ngo Chi Dung, General Director and Chairman of VNVC said, “Collaborating with Sanofi is an opportunity for Vietnam to access the world's leading vaccine production technology. It will empower the country to proactively produce hundreds of millions of doses of high-quality vaccines each year to serve domestic needs and even export.”
“The new facility strategically positions Sanofi and VNVC to meet the growing demand for essential vaccines—not only within Vietnam but also across neighboring countries. This development significantly strengthens the region's ability to respond to potential pandemic threats,” said a senior analyst at Coherent Market Insights (CMI).
The opening of the new facility and the technology transfer will enable Vietnam to quickly access leading modern technologies. This will help optimize research and development activities. Additionally, it will allow for the prompt servicing of domestic needs as well as firmly ensure national health security.
The collaboration between Sanofi and VNVC highlights the growing trend of partnerships in the vaccine technologies industry. Other vaccine manufacturers may follow Sanofi’s lead by expanding their presence in lucrative markets such as Vietnam and Africa through these inorganic growth strategies.
According to Coherent Market Insights (CMI), the global vaccine technologies market is forecast to exhibit a CAGR of 10.5% during the forecast period. Total industry size will likely expand from USD 55.44 Bn in 2025 to USD 111.52 Bn by 2032.
Source:
News Outlet: Reuters
